Linezolid

Generic Name: Linezolid

Brand Names: Zyvox, Zyvoxam

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₀FN_₃O_₄

CAS Number: 165800-03-3

Unique Ingredient Identifier: ISQ9I6J12J

Background: Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...

Indication: Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...

Associated Conditions: Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection

Associated Therapies: -

Clinical Trials

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Conditions: Tuberculous Meningitis

Interventions: Drug: Linezolid

First Posted Date: 2019-04-02

Last Posted Date: 2019-04-02

Lead Sponsor: Huashan Hospital

Target Recruit Count: 150

Registration Number: NCT03898635

Locations: 🇨🇳
Infectious department of Huashan Hospital, Fudan University, Shanghai, China

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Phase 2

Recruiting

Conditions: Tuberculosis, Multidrug-Resistant

Interventions: Drug: Delamanid
Drug: Levofloxacin
Drug: Bedaquiline
Drug: Clofazimine
Drug: Linezolid

First Posted Date: 2019-02-04

Last Posted Date: 2024-04-12

Lead Sponsor: Boston University

Target Recruit Count: 220

Registration Number: NCT03828201

Locations: 🇻🇳
National Lung Hospital, Hanoi, Vietnam
🇵🇭
De La Salle Health Sciences Institute, Dasmariñas, Philippines

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Phase 2

Completed

Conditions: Infectious Skin Disease
Bacterial Skin Disease

Interventions: Drug: PTK 0796
Drug: Linezolid

First Posted Date: 2018-10-23

Last Posted Date: 2020-10-12

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 234

Registration Number: NCT03716024

Locations: 🇺🇸
Paratek Recruiting Site, Wichita Falls, Texas, United States

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Phase 3

Completed

Conditions: Hospital-Acquired Bacterial Pneumonia
Ventilator-Associated Bacterial Pneumonia

Interventions: Drug: IMI/REL FDC
Drug: PIP/TAZ FDC
Drug: Linezolid

First Posted Date: 2018-07-11

Last Posted Date: 2023-06-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 274

Registration Number: NCT03583333

Locations: 🇨🇳
Peking University First Hospital ( Site 0131), Beijing, Beijing, China
🇨🇳
Zhongshan Hospital Affiliated to Xiamen University ( Site 0133), Xiamen, Fujian, China
🇨🇳
The Seventh Medical Center of PLA General Hospital-Intensive medicine ( Site 0157), Beijing, Beijing, China

and more 65 locations

Pharmacokinetic Study of Linezolid for TB Meningitis

Phase 2

Completed

Conditions: Linezolid
Tuberculosis, Meningeal

Interventions: Drug: Linezolid

First Posted Date: 2018-05-25

Last Posted Date: 2023-09-06

Lead Sponsor: Universitas Padjadjaran

Target Recruit Count: 36

Registration Number: NCT03537495

Locations: 🇮🇩
Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Linezolid
Drug: Clofazimine
Drug: Rifapentine
Drug: Levofloxacin
Drug: Bedaquiline

First Posted Date: 2018-03-22

Last Posted Date: 2023-08-14

Lead Sponsor: University College, London

Target Recruit Count: 675

Registration Number: NCT03474198

Locations: 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬
Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬
Infectious Diseases Institute, Kampala, Uganda

and more 14 locations

Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

Phase 3

Completed

Conditions: Tuberculosis, Multidrug-Resistant
XDR-TB
Extensively Drug-Resistant Tuberculosis
Tuberculosis, Pulmonary
Tuberculosis
Tuberculosis, MDR
Pre-XDR-TB

Interventions: Drug: Pretomanid
Drug: Linezolid
Drug: Bedaquiline
Drug: Placebo Linezolid

First Posted Date: 2017-03-22

Last Posted Date: 2023-06-29

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 181

Registration Number: NCT03086486

Locations: 🇿🇦
Tshepong Hospital, Klerksdorp, North - West, South Africa
🇲🇩
Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova, Republic of
🇷🇺
Moscow City Research and Practice Tuberculosis Treatment Centre, Moscow, Russian Federation

and more 8 locations